How Regulatory Affairs Works With Marketing

Every other cross-functional relationship in this job is mostly about whether something is true. This one is about whether something is true and persuasive at the same time, which is a harder question, and it’s where regulatory affairs earns or loses its credibility with the rest of the company fastest.

In brief

Regulatory’s job in a promotional review isn’t just legal exposure — it’s confirming a claim says only what the cleared or approved labeling actually supports, which is a narrower question than whether the claim is true.
The federal hook is broad on purpose: a false or misleading label statement is enough on its own to misbrand a product under the FD&C Act (21 U.S.C. § 352(a)); for prescription drugs, 21 CFR § 202.1 adds specific requirements like fair balance and a brief summary of risk.
The version of a claim marketing wants to run and the version regulatory can defend are usually close, not opposite — most real fights are about scope and comparison, not fabrication.
Bringing regulatory in at the concept stage rather than the final proof is what keeps this a collaboration instead of a bottleneck marketing routes around.

What a claim actually has to match

The standard isn’t whether a claim is medically defensible in the abstract — it’s whether it stays inside what was actually reviewed. The indications for use statement a device cleared under, or the labeling a drug was approved under, is the boundary regulatory is actually checking against, and that boundary can be narrower than what the science alone would support. A device that performs well in a population outside its cleared indication isn’t automatically fair game for a claim about that population — the clearance doesn’t cover it yet, however good the underlying data looks. That distinction is usually the actual content of a regulatory pushback on a marketing claim, not a disagreement about whether the underlying science holds up.

Where the friction actually comes from

The relationship breaks down less often over disagreement than over timing. A creative concept that’s already been through legal, design, and a media buy is expensive to change, and that’s exactly the point in the process where regulatory feedback lands hardest and gets the most resistance. Comparative claims are the other recurring friction point: internal data that convinces a product team doesn’t automatically substantiate a claim the way FDA or a competitor’s lawyers would read it, and “a competitor says something similar” isn’t a defense — it’s a description of a claim nobody has tested yet. The relationship works best on the same footing as regulatory’s relationship with clinical operations: a standing habit of early involvement, not a gate installed at the end.

Where this goes wrong

Reviewing the final proof instead of the concept

Regulatory sees a claim for the first time after it’s already been through design and media buying, which turns every note into a costly rework instead of a cheap adjustment.

Treating “medically true” as the same as “on-label”

A claim can be accurate and still outside what the approved or cleared labeling actually supports; regulatory is checking the second thing, not the first.

Assuming a competitor’s similar claim clears the bar

A claim already running elsewhere hasn’t been vetted against your own data or your own labeling, and FDA doesn’t treat “someone else said it too” as substantiation.

None of this makes regulatory the department that says no. It makes regulatory the department that knows exactly where the line is drawn on paper, which is a different and more useful thing to bring to a meeting than an opinion about what sounds compelling.

Sources & further reading

FD&C Act § 502(a), 21 U.S.C. § 352(a) — misbranding by false or misleading labeling fda.gov
21 CFR § 202.1 — Prescription Drug Advertisements ecfr.gov
Regulatory Academy — Writing an Indications for Use Statement You Can Defend regulatoryacademy.com
Regulatory Academy — How Regulatory Affairs Works With Clinical regulatoryacademy.com

This essay is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal, regulatory, or career advice.